BIOMAT Database Logo BIOMAT Database Logo

In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. 1997

J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
Department of Clinical Microbiology, Erasmus University Hospital Rotterdam, The Netherlands.

The activity of quinupristin/dalfopristin was compared with that of other widely used antibiotics against 355 strains isolated from patients with endocarditis. MICs were determined by a standard agar dilution method. Quinupristin/dalfopristin was inhibitory at 1 mg/L for all coagulase-negative staphylococci (n = 36) and for the majority of Staphylococcus aureus strains (n = 87). The activity of quinupristin/dalfopristin against 186 viridans streptococci was somewhat dependent on the species, with MIC50s ranging from 0.5 to 2 mg/L, being least active against Streptococcus bovis and most active against Streptococcus gordonii and Streptococcus mitis. For the staphylococci, quinupristin/dalfopristin was as active against erythromycin-susceptible as erythromycin-resistant strains. Viridans streptococci showed a slight but significant correlation between sensitivity to erythromycin and quinupristin/dalfopristin. It is concluded that quinupristin/dalfopristin has the potential to treat serious infections such as endocarditis caused by Gram-positive cocci.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004697 Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. Bacterial Endocarditides,Bacterial Endocarditis,Endocarditides, Bacterial
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013291 Streptococcus A genus of gram-positive, coccoid bacteria whose organisms occur in pairs or chains. No endospores are produced. Many species exist as commensals or parasites on man or animals with some being highly pathogenic. A few species are saprophytes and occur in the natural environment.
D014769 Virginiamycin A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry. Staphylomycin,Antibiotic 899,Eskalin,Founderguard,Stajac,Virgimycine

Related Publications

J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
February 2000, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
May 2002, Antimicrobial agents and chemotherapy,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro effectiveness of quinupristin/dalfopristin against Staphylococcus aureus strains.
May 2003, International journal of antimicrobial agents,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro activity of quinupristin/dalfopristin against selected bacterial pathogens isolated in Italy.
August 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
May 1997, The Journal of antimicrobial chemotherapy,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci.
November 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
December 2004, The Indian journal of medical research,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus.
May 1997, The Journal of antimicrobial chemotherapy,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.
March 1995, Diagnostic microbiology and infectious disease,
J W Mouton, and H P Endtz, and J G den Hollander, and N van den Braak, and H A Verbrugh
In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.
September 1996, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!